• Anti-MiTF antibody [C5/D5] (STJ16100393)

Anti-MiTF antibody [C5/D5] (STJ16100393)

SKU:
STJ16100393

Shipping:
Free Shipping
Current Stock:
Host: Mouse
Applications: IHC-P
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-MiTF is suitable for use in Immunohistochemistry research applications.
Clonality: Monoclonal
Clone ID: C5/D5
Conjugation: Unconjugated
Isotype: IgG1
Formulation: Tris Buffer, pH 7.3-7.7, containing 1% BSA and <0.1% Sodium Azide
Dilution Range: IHC 1:100 – 1:500
Storage Instruction: Store at 2-8°C upon receipt.
Gene Symbol: MITF
Gene ID: 4286
Uniprot ID: MITF_HUMAN
Tissue Specificity Expressed in melanocytes (at protein level). Isoform A2: Expressed in the retinal pigment epithelium, brain, and placenta. Expressed in the kidney. Isoform C2: Expressed in the kidney and retinal pigment epithelium. Isoform H1: Expressed in the kidney. Isoform H2: Expressed in the kidney. Isoform M1: Expressed in melanocytes. Isoform Mdel: Expressed in melanocytes.
Post Translational Modifications When nutrients are present, phosphorylation by MTOR at Ser-5 via non-canonical mTORC1 pathway promotes ubiquitination by the SCF(BTRC) complex, followed by degradation. Phosphorylation at Ser-405 significantly enhances the ability to bind the tyrosinase promoter. Phosphorylation by MARK3/cTAK1 at Ser-280 promotes association with 14-3-3/YWHA adapters and retention in the cytosol. Phosphorylated at Ser-180 and Ser-516 following KIT signaling, triggering a short live activation: Phosphorylation at Ser-180 and Ser-516 by MAPK and RPS6KA1, respectively, activate the transcription factor activity but also promote ubiquitination and subsequent degradation by the proteasome. Phosphorylated in response to blue light (415nm). Ubiquitinated by the SCF(BTRC) and SCF(FBXW11) complexes following phosphorylation ar Ser-5 by MTOR, leading to its degradation by the proteasome. Ubiquitinated following phosphorylation at Ser-180, leading to subsequent degradation by the proteasome. Deubiquitinated by USP13, preventing its degradation.
Function Transcription factor that acts as a master regulator of melanocyte survival and differentiation as well as melanosome biogenesis. Binds to M-boxes (5'-TCATGTG-3') and symmetrical DNA sequences (E-boxes) (5'-CACGTG-3') found in the promoter of pigmentation genes, such as tyrosinase (TYR). Involved in the cellular response to amino acid availability by acting downstream of MTOR: in the presence of nutrients, MITF phosphorylation by MTOR promotes its inactivation. Upon starvation or lysosomal stress, inhibition of MTOR induces MITF dephosphorylation, resulting in transcription factor activity. Plays an important role in melanocyte development by regulating the expression of tyrosinase (TYR) and tyrosinase-related protein 1 (TYRP1). Plays a critical role in the differentiation of various cell types, such as neural crest-derived melanocytes, mast cells, osteoclasts and optic cup-derived retinal pigment epithelium.
Protein Name Microphthalmia-Associated Transcription Factor
Class E Basic Helix-Loop-Helix Protein 32
Bhlhe32
Database Links Reactome: R-HSA-3232118
Cellular Localisation Nucleus
Cytoplasm
Lysosome Membrane
When Nutrients Are Present
Recruited To The Lysosomal Membrane Via Association With Gdp-Bound Ragc/Rragc (Or Ragd/Rragd): It Is Then Phosphorylated By Mtor
Phosphorylation By Mtor Promotes Ubiquitination And Degradation
Conversely
Inhibition Of Mtorc1
Starvation And Lysosomal Disruption
Promotes Dephosphorylation And Translocation To The Nucleus
Phosphorylation By Mark3/Ctak1 Promotes Association With 14-3-3/Ywha Adapters And Retention In The Cytosol
Alternative Antibody Names Anti-Microphthalmia-Associated Transcription Factor antibody
Anti-Class E Basic Helix-Loop-Helix Protein 32 antibody
Anti-Bhlhe32 antibody
Anti-MITF antibody
Anti-BHLHE32 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance